Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers

K. Róna, K. Ary, G. Renczes, B. Gachályi, Gy Grézal, S. Drabant, I. Klebovich

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In a single dose, randomized, cross-over study, with one week of wash-out period, the relative bioavailability of Dopegyt® tablets containing 250 mg alpha-methyldopa (AMD) and Presinol® film tablets with identical active ingredient content was examined in 24 healthy volunteers. Since technologically two completely different preparations (a film-tablet and a non-film-tablet) having significantly different in vitro dissolution were to be compared, both preparations were compared to a third one, AMD solution (Dopegyt® solution) with 250 mg/50 ml concentration. Plasma concentrations of the drug were measured for 24 hours post-dose, applying HPLC with fluorometric detection. Pharmacokinetic parameters calculated from individual data (AUCo-∞, AUCo-t, Cmax, Cmax/AUCo-∞ tmax) were evaluated statistically. Wilcoxon's nonparametric test and the four-way variance analysis could not detect any significant difference at the usual a=95% probability level in these pharmacokinetic parameters of the two tablet preparations. For AUCo-∞ at the 90% probability level, the confidence interval was 0.883-1.237 (with an estimated geometric mean of 1.045), for the test/reference ratio of Dopegyt® and Presinol® tablets, thus the two preparations proved to be bioequivalent. The relative bioavailability of Dopegyt® (test preparation) and Presinol® (reference preparation) calculated from the AUCo-∞ values was 116.7±56.7% that also confirmed bioequivalence. The results of all the applied statistical tests suggest that Dopegyt® and Presinol® can be considered as bioequivalent preparations.

Original languageEnglish
Pages (from-to)25-30
Number of pages6
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume26
Issue number1-2
Publication statusPublished - 2001

Fingerprint

Methyldopa
Biological Availability
Tablets
Oral Administration
Healthy Volunteers
Pharmacokinetics
Therapeutic Equivalency
Cross-Over Studies
Analysis of Variance
High Pressure Liquid Chromatography
Confidence Intervals
Pharmaceutical Preparations

Keywords

  • Alpha methyldopa
  • Bioavailability
  • Bioequivalence
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers. / Róna, K.; Ary, K.; Renczes, G.; Gachályi, B.; Grézal, Gy; Drabant, S.; Klebovich, I.

In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 26, No. 1-2, 2001, p. 25-30.

Research output: Contribution to journalArticle

@article{7720d77086704e0e9e7475036e9b347b,
title = "Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers",
abstract = "In a single dose, randomized, cross-over study, with one week of wash-out period, the relative bioavailability of Dopegyt{\circledR} tablets containing 250 mg alpha-methyldopa (AMD) and Presinol{\circledR} film tablets with identical active ingredient content was examined in 24 healthy volunteers. Since technologically two completely different preparations (a film-tablet and a non-film-tablet) having significantly different in vitro dissolution were to be compared, both preparations were compared to a third one, AMD solution (Dopegyt{\circledR} solution) with 250 mg/50 ml concentration. Plasma concentrations of the drug were measured for 24 hours post-dose, applying HPLC with fluorometric detection. Pharmacokinetic parameters calculated from individual data (AUCo-∞, AUCo-t, Cmax, Cmax/AUCo-∞ tmax) were evaluated statistically. Wilcoxon's nonparametric test and the four-way variance analysis could not detect any significant difference at the usual a=95{\%} probability level in these pharmacokinetic parameters of the two tablet preparations. For AUCo-∞ at the 90{\%} probability level, the confidence interval was 0.883-1.237 (with an estimated geometric mean of 1.045), for the test/reference ratio of Dopegyt{\circledR} and Presinol{\circledR} tablets, thus the two preparations proved to be bioequivalent. The relative bioavailability of Dopegyt{\circledR} (test preparation) and Presinol{\circledR} (reference preparation) calculated from the AUCo-∞ values was 116.7±56.7{\%} that also confirmed bioequivalence. The results of all the applied statistical tests suggest that Dopegyt{\circledR} and Presinol{\circledR} can be considered as bioequivalent preparations.",
keywords = "Alpha methyldopa, Bioavailability, Bioequivalence, Pharmacokinetics",
author = "K. R{\'o}na and K. Ary and G. Renczes and B. Gach{\'a}lyi and Gy Gr{\'e}zal and S. Drabant and I. Klebovich",
year = "2001",
language = "English",
volume = "26",
pages = "25--30",
journal = "European Journal of Drug Metabolism and Pharmacokinetics",
issn = "0378-7966",
publisher = "Springer Paris",
number = "1-2",

}

TY - JOUR

T1 - Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers

AU - Róna, K.

AU - Ary, K.

AU - Renczes, G.

AU - Gachályi, B.

AU - Grézal, Gy

AU - Drabant, S.

AU - Klebovich, I.

PY - 2001

Y1 - 2001

N2 - In a single dose, randomized, cross-over study, with one week of wash-out period, the relative bioavailability of Dopegyt® tablets containing 250 mg alpha-methyldopa (AMD) and Presinol® film tablets with identical active ingredient content was examined in 24 healthy volunteers. Since technologically two completely different preparations (a film-tablet and a non-film-tablet) having significantly different in vitro dissolution were to be compared, both preparations were compared to a third one, AMD solution (Dopegyt® solution) with 250 mg/50 ml concentration. Plasma concentrations of the drug were measured for 24 hours post-dose, applying HPLC with fluorometric detection. Pharmacokinetic parameters calculated from individual data (AUCo-∞, AUCo-t, Cmax, Cmax/AUCo-∞ tmax) were evaluated statistically. Wilcoxon's nonparametric test and the four-way variance analysis could not detect any significant difference at the usual a=95% probability level in these pharmacokinetic parameters of the two tablet preparations. For AUCo-∞ at the 90% probability level, the confidence interval was 0.883-1.237 (with an estimated geometric mean of 1.045), for the test/reference ratio of Dopegyt® and Presinol® tablets, thus the two preparations proved to be bioequivalent. The relative bioavailability of Dopegyt® (test preparation) and Presinol® (reference preparation) calculated from the AUCo-∞ values was 116.7±56.7% that also confirmed bioequivalence. The results of all the applied statistical tests suggest that Dopegyt® and Presinol® can be considered as bioequivalent preparations.

AB - In a single dose, randomized, cross-over study, with one week of wash-out period, the relative bioavailability of Dopegyt® tablets containing 250 mg alpha-methyldopa (AMD) and Presinol® film tablets with identical active ingredient content was examined in 24 healthy volunteers. Since technologically two completely different preparations (a film-tablet and a non-film-tablet) having significantly different in vitro dissolution were to be compared, both preparations were compared to a third one, AMD solution (Dopegyt® solution) with 250 mg/50 ml concentration. Plasma concentrations of the drug were measured for 24 hours post-dose, applying HPLC with fluorometric detection. Pharmacokinetic parameters calculated from individual data (AUCo-∞, AUCo-t, Cmax, Cmax/AUCo-∞ tmax) were evaluated statistically. Wilcoxon's nonparametric test and the four-way variance analysis could not detect any significant difference at the usual a=95% probability level in these pharmacokinetic parameters of the two tablet preparations. For AUCo-∞ at the 90% probability level, the confidence interval was 0.883-1.237 (with an estimated geometric mean of 1.045), for the test/reference ratio of Dopegyt® and Presinol® tablets, thus the two preparations proved to be bioequivalent. The relative bioavailability of Dopegyt® (test preparation) and Presinol® (reference preparation) calculated from the AUCo-∞ values was 116.7±56.7% that also confirmed bioequivalence. The results of all the applied statistical tests suggest that Dopegyt® and Presinol® can be considered as bioequivalent preparations.

KW - Alpha methyldopa

KW - Bioavailability

KW - Bioequivalence

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0034876931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034876931&partnerID=8YFLogxK

M3 - Article

C2 - 11554430

AN - SCOPUS:0034876931

VL - 26

SP - 25

EP - 30

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

SN - 0378-7966

IS - 1-2

ER -